研究发现,Ovarian癌症血液测试可能会错过黑人和美洲土著病人的病例。 Ovarian cancer blood test may miss cases in Black and Native American patients, study finds.

在JAMA Network Open上发表的一份新研究报告显示,卵巢癌的常见血液测试,即CA-125测试,可能会错过黑人和美洲土著病人的一些病例,导致治疗延迟。 A new study published in JAMA Network Open reveals that a common blood test for ovarian cancer, the CA-125 test, may miss some cases in Black and Native American patients, leading to delayed treatment. 研究者发现,与白人病人相比,这些病人在诊断时提高CA-125的CA-125水平的可能性低23%,这表明目前这些人群的测试阈值太高。 Researchers found these patients were 23% less likely to have elevated CA-125 levels at diagnosis compared to white patients, suggesting that current test thresholds are too high for these populations. 这项研究提出了一个新的、较低的测试门槛,以提高准确性并缩小保健差距。 The study proposes a new, lower threshold for the test to improve accuracy and reduce healthcare disparities.